1. Home
  2. Research
  3. Research Groups
  4. Molecular Pathology of Cancer Group

Molecular Pathology of Cancer Group

Search for publications

Only original articles, editorials, guidelines.

  • Solórzano JL, Menéndez V, Parra E, Solis L, Salazar R, García-Cosío M, Climent F, Fernández S, Díaz E, Francisco-Cruz A, Khoury J, Jiang M, Tamegnon A, Montalbán C, Melero I, Wistuba I, De Andrea C, F García J.

    Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma.

    OncoImmunology . 13(1): 2388304-2388304. Number of citations: 7

    [doi:10.1080/2162402X.2024.2388304]

  • Riesco-Martinez MC, Capdevila J, Alonso V, Jimenez-Fonseca P, Teule A, Grande E, Sevilla I, Benavent M, Alonso-Gordoa T, Custodio A, Anton-Pascual B, Hernando J, Polo E, Castillo-Trujillo OA, Lamas-Paz A, Teijo A, Rodriguez-Gil Y, Soldevilla B, Garcia-Carbonero R.

    Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913).

    Nature Communications . 15(1): 6753-6753. Number of citations: 24

    [doi:10.1038/s41467-024-50969-8]

  • Martínez-Campelo L, Blanco-Verea A, López-Fernández T, Martínez-Monzonís A, Buño A, Mazón P, Zamora P, Norton N, Reddy JS, Velasco-Ruiz A, González-Neira A, Vulsteke C, Alonso-Gordoa T, Cruz R, Diz-de Almeida S, Carracedo A, González-Juanatey JR, López-Sendón J, Brion M.

    Meta-analysis of genome-wide association studies for cancer therapy-related cardiovascular dysfunction and functional mapping highlight an intergenic region close to TP63.

    Scientific Reports . 14(1): 18413-18413. Number of citations: 4

    [doi:10.1038/s41598-024-69064-5]

  • Albarrán V, Guerrero P, de Quevedo CG, González C, Chamorro J, Rosero DI, Moreno J, Calvo JC, de Aguado PP, Alía V, Sotoca P, Barrill AM, Román MS, Álvarez-Ballesteros P, Serrano JJ, Soria A, Olmedo ME, Saavedra C, Cortés A, Gómez A, Lage Y, Ruiz Á, Ferreiro MR, Longo F, Garrido P, Gajate P.

    Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependent.

    CANCER IMMUNOLOGY IMMUNOTHERAPY . 73(10): 186-186. Number of citations: 26

    [doi:10.1007/s00262-024-03772-9]

  • Perez-Navarro E, Conteduca V, Funes JM, Dominguez JI, Martin-Serrano M, Cremaschi P, Fernandez-Perez MP, Gordoa TA, Font A, Vázquez-Estévez S, González-Del-Alba A, Wetterskog D, Mellado B, Fernandez-Calvo O, Méndez-Vidal MJ, Climent MA, Duran I, Gallardo E, Rodriguez Sanchez A, Santander C, Sáez MI, Puente J, Tudela J, Marinas C, López-Andreo MJ, Castellano D, Attard G, Grande E, Rosino A, Botia JA, Palma-Mendez J, De Giorgi U, Gonzalez-Billalabeitia E.

    Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer.

    Cancers . 16(14): . Number of citations: 2

    [doi:10.3390/cancers16142535]

  • Rubio MJ, Manzano A, de Sande LM, Estévez-García P, Gordon MDM, de Prado DS, de Aranguiz BHF, Guerra-Alia EM, Carbó-Bagué A, Romero I, Corbellas M, González-Haba A, Robles-Barraza CE, Martínez-García J, González-Martín A.

    Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study.

    BMC CANCER . 24(1): 803-803. Number of citations: 3

    [doi:10.1186/s12885-024-12577-z]

  • Martínez-Jañez N, Ezquerra MB, Manso Sanchez LM, Carrasco FH, Torres AA, Morales S, Ortega PT, Gil VLO, Sampedro T, Conejero RA, Calvo-Martinez L, Galve-Calvo E, López R, de la Pena FA, Lopez-Tarruella S, de Araguiz BAHF, Ruiz LB, Cardenas TM, Chacon JI, Antón FM.

    First-line therapy with palbociclib in patients with advanced HR(+)/HER2(-) breast cancer: The real-life study PALBOSPAIN.

    BREAST CANCER RESEARCH AND TREATMENT . 206(2): 317-328. Number of citations: 10

    [doi:10.1007/s10549-024-07287-w]

  • Araujo-Castro M, Biagetti B, Menéndez Torre E, Novoa-Testa I, Cordido F, Pascual-Corrales E, Rodríguez Berrocal V, Guerrero-Pérez F, Vicente A, Percovich Hualpa JC, García-Centeno R, González-Fernández L, Ollero García MD, Irigaray Echarri A, Moure Rodríguez MD, Novo-Rodríguez C, Calatayud M, Villar-Taibo R, Bernabéu I, Alvarez-Escola C, Benítez Valderrama P, Tenorio-Jiménez C, Abellán Galiana P, Venegas E, González-Molero I, Iglesias P, Blanco-Carrera C, Vidal-Ostos De Lara F, de Miguel Novoa P, López Mezquita E, Hanzu FA, Aldecoa I, Aznar S, Lamas C, Aulinas A, Asla Q, Gracia Gimeno P, Recio-Córdova JM, Avilés-Pérez MD, Asensio-Wandosell D, Sampedro-Núñez M, Cámara R, Paja Fano M, Ruz-Caracuel I, Fajardo C, Marazuela M, Puig-Domingo M.

    Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs.

    ENDOCRINE-RELATED CANCER . 31(7): . Number of citations: 9

    [doi:10.1530/ERC-24-0043]

  • Menéndez V, Solórzano JL, García-Cosío M, Cereceda L, Díaz E, Estévez M, Roncador G, Vega Z, Montalbán C, Kulasinghe A, García JF.

    Mapping the spatial dynamics of the CD4+ T cell spectrum in classical Hodgkin lymphoma.

    MODERN PATHOLOGY . 37(9): 100551-100551. Number of citations: 8

    [doi:10.1016/j.modpat.2024.100551]

  • Colomer R, González-Farré B, Ballesteros AI, Peg V, Bermejo B, Pérez-Mies B, de la Cruz S, Rojo F, Pernas S, Palacios J.

    Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

    Clinical & Translational Oncology . 26(12): 2935-2951. Number of citations: 31

    [doi:10.1007/s12094-024-03541-1]

  • Biagetti B, Araujo-Castro M, Torre EM, Novoa-Testa I, Cordido F, Corrales EP, Berrocal VR, Guerrero-Pérez F, Vicente A, Percovich JC, Centeno RG, González L, García MDO, Echarri AI, Rodríguez MDM, Novo-Rodríguez C, Calatayud M, Villar-Taibo R, Bernabéu I, Alvarez-Escola C, Valderrama PB, Tenorio-Jiménez C, Galiana PA, Moreno EV, Molero IG, Iglesias P, Blanco C, De Lara FV, de Miguel P, Mezquita EL, Hanzu F, Aldecoa I, Aznar S, Lamas C, Aulinas A, Asla Roca Q, Gracia P, Córdova JMR, Aviles M, Asensio-Wandosel D, Sampedro M, Cámara R, Paja M, Ruz-Caracuel I, Fajardo-Montañana C, Asanza EC, Martinez-Saez E, Marazuela M, Puig-Domingo M.

    Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion.

    EUROPEAN JOURNAL OF ENDOCRINOLOGY . 190(6): 458-466. Number of citations: 11

    [doi:10.1093/ejendo/lvae053]

  • Alonso-Gordoa T, Goodman M, Vulsteke C, Roubaud G, Zhang J, Parikh M, Piulats JM, Azaro A, James GD, Cavazzina R, Gangl ET, Thompson J, Pouliot G, Kumar R, Sweeney C.

    A phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive, metastatic, castration-resistant prostate cancer.

    ESMO Open . 9(6): 103446-103446. Number of citations: 6

    [doi:10.1016/j.esmoop.2024.103446]

  • Agarwal N, Castellano D, Alonso-Gordoa T, Arranz Arija JA, Colomba E, Gravis G, Mourey L, Oudard S, Fléchon A, Gonzalez M, Maroto PM, Schweizer MT, Gallardo E, Johnston E, Balar A, Haddad N, Appiah AK, Nacerddine K, Piulats JM.

    A Signal-finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1.

    CLINICAL CANCER RESEARCH . 30(11): 2377-2383.

    [doi:10.1158/1078-0432.CCR-23-3436]

  • Makker V, Perez-Fidalgo JA, Valabrega G, Hamilton E, Van Gorp T, Sehouli J, Reginácová K, Richardson DL, Perri T, Oza AM, Miller DS, Alía EMG, De Giorgi U, Henry S, Spitz DL, Wimberger P, Bednaríková M, Chon HS, Martínez-Garcia J, Pisano C, Berek JS, Romero I, Scambia G, Fariñas-Madrid L, Buscema J, Schochter F, Li K, Kalyanapu P, Walker CJ, Vergote I.

    Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.

    Gynecologic Oncology . 185: 202-211. Number of citations: 24

    [doi:10.1016/j.ygyno.2024.05.016]

  • Fernández-Miranda I, Pedrosa L, González-Rincón J, Espinet B, de la Cruz Vicente F, Climent F, Gómez S, Royuela A, Camacho FI, Martín-Acosta P, Yanguas-Casás N, Domínguez M, Méndez M, Colomo L, Salar A, Horcajo B, Navarro M, García-Cosío M, Piris-Villaespesa M, Llanos M, García JF, Sequero S, Mercadal S, García-Hernández S, Navarro B, Mollejo M, Provencio M, Sánchez-Beato M.

    Generation and External Validation of a Histologic Transformation Risk Model for Patients with Follicular Lymphoma.

    MODERN PATHOLOGY . 37(7): 100516-100516. Number of citations: 5

    [doi:10.1016/j.modpat.2024.100516]

  • Borque-Fernando Á, Zapatero A, Manneh R, Alonso-Gordoa T, Couñago F, Domínguez-Esteban M, López-Valcárcel M, Rodríguez-Antolín A, Sala-González N, Sanmamed N, Maroto P.

    Recommendations on the treatment of metastatic hormone-sensitive prostate cancer: Patient selection.

    Actas Urologicas Espanolas . 48(9): 623-631. Number of citations: 5

    [doi:10.1016/j.acuroe.2024.05.008]

  • Pothuri B, Han S, Chase DM, Heitz F, Burger RA, Gaba L, Van Le L, Guerra E, Bender D, Korach J, Cloven N, Churruca C, Follana P, DiSilvestro P, Baurain JF, Jardon K, Pisano C, Peen U, Mäenpää J, Gupta D, Bacqué E, Li Y, Compton N, Antonova J, Monk BJ, González-Martín A.

    Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.

    Gynecologic Oncology . 184: 168-177. Number of citations: 15

    [doi:10.1016/j.ygyno.2024.01.021]

  • López-Gil JC, García-Silva S, Ruiz-Cañas L, Navarro D, Palencia-Campos A, Giráldez-Trujillo A, Earl J, Dorado J, Gómez-López G, Monfort-Vengut A, Alcalá S, Gaida MM, García-Mulero S, Cabezas-Sáinz P, Batres-Ramos S, Barreto E, Sánchez-Tomero P, Vallespinós M, Ambler L, Lin ML, Aicher A, García García de Paredes A, de la Pinta C, Sanjuanbenito A, Ruz-Caracuel I, Rodríguez-Garrote M, Guerra C, Carrato A, de Cárcer G, Sánchez L, Nombela-Arrieta C, Espinet E, Sanchez-Arevalo Lobo VJ, Heeschen C, Sainz B Jr.

    The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells.

    GUT . 73(9): 1489-1508. Number of citations: 15

    [doi:10.1136/gutjnl-2023-330995]